Hybrid Skin Booster · PDLLA + HA

JUVELOOK in Seoul | PDLLA Skin Booster with Same-Day Softening

JUVELOOK is a hybrid skin booster combining poly-D,L-lactic acid (PDLLA) microspheres with a hyaluronic acid (HA) carrier — manufactured by Korea's VAIM Co., Ltd. The HA component delivers same-day softening, and PDLLA stimulates collagen synthesis over 6-12 weeks. Note: JUVELOOK is MFDS-approved in Korea but is not FDA-approved in the United States.

JUVELOOK — Hybrid Skin Booster · PDLLA + HA

Reviewed by Dr. SangYoul Yun

Board-certified Dermatologist · Chief Director · AAD Member

Overview

JUVELOOK PDLLA + hyaluronic-acid hybrid skin booster at Delight Dermatology in Gangnam Seoul — same-day softening with collagen stimulation over 6-12 weeks. Board-certified dermatologist consultation.

Best for

Skin texture irregularity, fine lines, periorbital tone, and pore size
Tear trough rejuvenation and lower-eyelid skin quality
Mild-to-moderate volume loss for structural rejuvenation (JUVELOOK Volume / LENISNA formulation)
Patients comparing PDLLA biostimulators with Sculptra (PLLA), Rejuran (PN), or HA boosters

Suited for

Patients wanting collagen stimulation with immediate same-day softening from the HA carrier
Patients who plateaued on HA boosters and want gradual structural improvement
Tear trough and periorbital patients (with appropriate cannula technique per Lau 2025 consensus)
Korean clinical-tourism patients seeking a widely-used Korean PDLLA biostimulator (market-share figures are not publicly disclosed; JUVELOOK is among the leading PDLLA brands in Korean Gangnam clinic menus)
Patients who can commit to a 3-session protocol over 9-18 weeks (3-6 week intervals)

Duration: 20-30 min (per area, full face); cannula technique for periorbital adds ~10 min
Sessions: 3 induction (3-6 wk apart); maintenance not yet standardized (>12 mo data not published)
Downtime: ~1 week swelling resolution
Peak result: Week 6-12 post-induction; sustained at 6 months in published series

Timeline

Immediately post
Same-day softening visible from HA carrier component; mild local edema and erythema from injection.
Days 1-7
Swelling (29-43% in published series) and mild bruising (~11%) resolve. Initial HA softening continues to settle.
Week 2-4
HA carrier integration complete. Collagen response begins (animal histology models show TGF-β1 / collagen-III rise).
Week 6-12
PDLLA-driven collagen-type-I synthesis becomes visible; cumulative texture and structure improvement after sessions 2-3.
Month 6
Sustained effect; patient series (PMID 42098500, 41777074) report continued GAIS improvement. No published data extending beyond 12 months.

Devices

JUVELOOK (VAIM PDLLA + HA Hybrid)

VAIM Co., Ltd. (Korea)MFDS-approved Class IV medical device (Korea, ~2021 base + JUVELOOK Volume / LENISNA line extension); CE-marked in EU; NOT FDA-approved as injectable in the US

Key specs

Active ingredient: poly-D,L-lactic acid (PDLLA) microspheres + non-crosslinked HA carrier
Mechanism: HA delivers same-day softening; PDLLA triggers fibroblast collagen synthesis over 6-12 weeks
Variants: base JUVELOOK (skin booster) / JUVELOOK Volume = LENISNA (deeper volumization)
Course: 3 sessions, 3-6 week intervals; cannula for periorbital + tear trough
Evidence: ~250 patients across published series, thinner than Sculptra (25+ years)

Process

01
Dermatologist evaluates skin concern depth, treatment goal (texture vs structure), and prior injectable history — including lidocaine/amide-anesthetic sensitivity (JUVELOOK reconstitution includes lidocaine), recent isotretinoin or oral retinoid use (relative contraindication for biostimulators), and dental work or active infection in proximity to the injection zone
02
Variant selection: base JUVELOOK (skin booster, superficial/mid-dermis) vs JUVELOOK Volume / LENISNA (deeper volumization with ~4× higher PDLLA dose)
03
Reconstitution is shorter than Sculptra historically required (Su 2025 comparator study, PMID 41516868); same-day reconstitution permitted by manufacturer protocol
04
Topical anesthesia applied; cannula strongly preferred for tear trough and high-vascular-risk areas (Lau 2025 consensus, PMID 41359890)
05
Session typically 20-30 minutes per area; induction protocol = 3 sessions at 3-6 week intervals (most published series use this cadence)

Aftercare

01First 24-48 hours
Avoid heat exposure (sauna, hot yoga, hot shower), intense exercise, and facial massage. Cool compress permitted if comfortable. Avoid touching or pressing injection sites. **Emergency signs requiring immediate clinic contact**: sudden severe pain disproportionate to procedure, vision change or blurring, blanching or unusual skin colour change at or near injection site, persistent bleeding — these may indicate rare vascular events (Lau 2025 consensus, PMID 41359890) and need urgent assessment.
02Days 3-7
Resume normal skincare gradually. Avoid retinoids and exfoliating acids until skin settles. Broad-spectrum SPF 50+ daily.
03Week 2-4
Schedule next session at 3-6 week interval per induction protocol. Continue strict sun protection — UV degrades the collagen the PDLLA is building.
04Long-term
Daily SPF 50+. If any persistent nodule or unusual swelling appears, contact clinic immediately — published management protocol uses monopolar RF (Seo 2024, PMID 39283001).

FAQ

Is JUVELOOK FDA-approved?

No. JUVELOOK is NOT cleared by the US FDA as an injectable. It is MFDS-approved as a medical device in Korea (since approximately 2021) and CE-marked in the EU. Several Gangnam clinic marketing pages incorrectly claim FDA approval — likely confusion with Sculptra (PLLA, manufactured by Galderma), which is FDA-approved and is a different molecule (L-isomer only, not the D,L racemic mixture in JUVELOOK). Honest regulatory framing is part of board-certified Anti-Aging specialist standards.

How is JUVELOOK different from Sculptra?

Both are biostimulators that trigger fibroblast-driven collagen synthesis, but they differ in molecule, particle size, and formulation. Sculptra uses pure L-isomer PLLA (~40-63 μm crystalline microspheres), is FDA-approved with 25+ years of clinical evidence, and historically required pre-hydration. JUVELOOK uses D,L racemic PDLLA (~20 μm amorphous microspheres, per Jang 2026 PMID 42049428) pre-mixed with HA carrier for same-day reconstitution and immediate softening. An independent SNU/Sookmyung mouse comparator (PMID 42049428) showed PLLA produced greater collagen area than PDLLA at 12 weeks — so 'JUVELOOK better than Sculptra' is not supported by published data. The honest difference is formulation engineering: JUVELOOK offers faster reconstitution, smaller particles, and HA-driven immediate softening; Sculptra offers a longer global evidence track record.

What is the difference between JUVELOOK and JUVELOOK Volume?

Same active ingredients (PDLLA + HA) but different formulations. Base JUVELOOK uses smaller particles for superficial-to-mid-dermal skin boosting (texture, fine lines, periorbital). JUVELOOK Volume — sold internationally as LENISNA — has approximately 4× higher PDLLA dose (~170 mg vs ~42.5 mg) and a thicker HA carrier for deep-dermal or subcutaneous volumization (mid-face, deep tear trough, jawline). Variant clarity matters: JUVELOOK Volume and LENISNA on different clinic menus are the same product.

How many sessions and how soon will I see results?

Typical induction is 3 sessions at 3-6 week intervals — the protocol used in most published JUVELOOK papers (tear trough: PMID 42098500; lower eyelid: PMID 40017393; pore reduction: PMID 40469551). The HA carrier provides subtle same-day softening; collagen-driven change becomes visible at 6-12 weeks and continues developing for several months. There is currently no published JUVELOOK study extending past 12 months — durability beyond that is not yet established by peer-reviewed data.

What are the most serious risks?

Rare but serious: vascular occlusion, including blindness, from inadvertent intravascular injection — particularly in glabellar, periorbital, and forehead zones. The Lau 2025 expert consensus on PDLLA-HA200-induced visual impairment (PMID 41359890) is the authoritative safety document; clinic protocol should reflect its key safe-injection messages (cannula for high-risk zones, hyaluronidase emergency kit, anatomy-based depth control). Common transient risks include swelling, bruising, and mild erythema (~7-43% across published series); rare late-onset nodules have been documented — one published JUVELOOK tear-trough nodule case fully resolved with monopolar RF (Seo 2024, PMID 39283001).

Notice

Tell the dermatologist at consultation if any of the following apply.

Active skin infection or inflammation at injection site
Severe allergy or hypersensitivity to product components (including lidocaine — JUVELOOK contains it)
Active autoimmune connective tissue disease (relative)
History of granuloma with PLLA or other biostimulators (relative)
Pregnancy or lactation (no data — defer elective)
Keloid tendency or active dermatitis at injection site
Recent procedures: permanent filler ≤4 weeks, oral retinoid ≤6 months, dental work ≤2 weeks (relative)
Active bleeding diathesis or recent anticoagulant use without clearance

For your visit

Mild swelling and possible bruising for about 1 week; transient redness common (29-43% across published series)
Avoid intense exercise, heat exposure, and facial massage for 24-48 hours; same-day softening visible from the HA carrier
A full 3-session course takes about 9-18 weeks (3-6 week intervals). Short-trip patients usually complete 1 session in Korea and continue at home or on a return visit

References

The clinical claims on this page — device specs, efficacy timelines, safety profile — are supported by the primary sources below. Each citation links to the original paper or regulatory record.

[1]Hybrid PDLLA-HA for Tear Trough Rejuvenation. Aesthetic Plast Surg (Young & Lau, PMID 42098500) — prospective study N=15 (2026).
[2]Safe Injection Technique for PDLLA-HA200 (Visual Impairment Consensus). J Craniofac Surg (Lau et al., PMID 41359890) — authoritative safety consensus (2025).
[3]PDLLA for Lower Eyelid Rejuvenation: Efficacy and Safety. J Cosmet Dermatol (Wan et al., PMID 40017393) — tear-trough series, 6-month follow-up (2025).
[4]Microneedling + Topical PDLLA for Pore + Texture Improvement. Plast Reconstr Surg Glob Open (Wan et al., PMID 40469551) — N=15, 22-week follow-up (2025).
[5]PLLA vs PDLLA Fillers: Comparative Mouse Study. In Vivo (Jang et al., PMID 42049428) — independent SNU/Sookmyung comparator (2026).
[6]Energy-Based Management of PDLLA Tear-Trough Nodule. J Cosmet Dermatol (Seo et al., PMID 39283001) — RF rescue case report (2024).

Reviewed byDr. SangYoul Yun· Board-Certified Dermatologist · AAD International Fellow (IFAAD)· Last reviewed 2026-05-14

Related procedures

ProcedureSkin Botox in Seoul | Micro-Dose Pore & Texture RefinementSkin Botox (meso-botox) in Seoul: diluted toxin into the dermis to shrink pores, reduce oil, and smooth texture — no frozen expression.

ProcedureElravie Re2O in Seoul | 4th-Generation ECM Booster (hADM)Elravie Re2O in Seoul — the world's first ECM booster using human-derived dermal matrix (hADM) from Humedix Korea for direct structural skin restoration.

ProcedureSKINVIVE by JUVÉDERM in Seoul | FDA-Approved Skin Quality InjectableSKINVIVE by JUVÉDERM in Seoul — manufactured by Allergan Aesthetics (AbbVie). FDA-approved in May 2023 as the first HA microdroplet injectable indicated for cheek smoothness improvement.

ProcedureRejuran in Seoul | Polynucleotide Skin Repair & Barrier RecoveryRejuran polynucleotide skin booster at Delight Dermatology in Gangnam Seoul — regenerative injectable for skin texture, fine lines, and post-procedure recovery. Board-certified dermatologist consultation.

Notice: Individual results may vary depending on skin condition, treatment history, and recovery factors. All treatment plans are determined through individual consultation with a board-certified dermatologist. The information on this page is for reference only and does not constitute medical advice or guarantee specific outcomes.

Next Step

You can start with a short message before deciding on JUVELOOK.

Even a short first message can help you check suitability, timing, and what to compare next before you book.

Contact

WhatsApp KakaoTalk LINE